
Also known as Reta
Investigational triple agonist targeting GLP-1, GIP and glucagon receptors — 20mg, 30mg, 40mg and 60mg lyophilised vials at 99%+ purity for in vitro research.
Best value and fastest option — supplied as a lyophilised vial, shipped within 48 hours of ordering. Use our calculator for your target concentration.
For In Vitro Use Only — Not for Human Use
Every batch is independently HPLC & mass-spec tested. Certificate of Analysis is batch-numbered and matched to the vial you receive.
Retatrutide (LY-3437943) is an investigational triple-receptor agonist that combines activity at the GLP-1, GIP and glucagon receptors in a single 39-residue peptide backbone. Supplied as a sterile lyophilised powder in 20mg, 30mg, 40mg and 60mg vials, each batch is verified to 99%+ purity by RP-HPLC and mass spectrometry.
Retatrutide is used in vitro to study the combined pharmacology of incretin (GLP-1, GIP) and glucagon receptor signalling in a single molecule. Research groups compare it head-to-head against dual agonists (e.g. Tirzepatide) to characterise receptor bias, cAMP response, and peptide stability across long incubation windows.